NeoGenomics (NEO) News Today $15.28 -0.08 (-0.52%) (As of 11:20 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Segall Bryant & Hamill LLC Has $27.93 Million Stake in NeoGenomics, Inc. (NASDAQ:NEO)Segall Bryant & Hamill LLC increased its stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 67.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,893,407 shares of the medical research company's stock afterNovember 20 at 6:49 AM | marketbeat.comNeoGenomics, Inc. (NASDAQ:NEO) General Counsel Alicia C. Olivo Sells 5,175 SharesNovember 20 at 6:02 AM | insidertrades.comNeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized TreatmentNovember 19 at 12:35 PM | finance.yahoo.comLos Angeles Capital Management LLC Acquires New Stake in NeoGenomics, Inc. (NASDAQ:NEO)Los Angeles Capital Management LLC bought a new position in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 74,633 shares of the medical research company's stock, valued atNovember 15, 2024 | marketbeat.comNeoGenomics: Strong Growth Potential in Oncology Lab Testing Justifies Buy RatingNovember 8, 2024 | markets.businessinsider.comNeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 8, 2024 | finance.yahoo.comNeoGenomics Reports Strong Q3 2024 GrowthNovember 6, 2024 | markets.businessinsider.comNeoGenomics: Balancing Growth in NGS with ADx Challenges Amid Strategic ProgressNovember 6, 2024 | markets.businessinsider.comNeoGenomics' (NEO) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $19.00 target price on shares of NeoGenomics in a research note on Wednesday.November 6, 2024 | marketbeat.comQ3 2024 Neogenomics Inc Earnings CallNovember 6, 2024 | finance.yahoo.comNeoGenomics Third Quarter 2024 Earnings: EPS Beats ExpectationsNovember 6, 2024 | finance.yahoo.comNeoGenomics Reports Third Quarter 2024 ResultsNovember 5, 2024 | finanznachrichten.deTwo SW FL companies report earnings on Election Day. Here's a look at how they performedNovember 5, 2024 | msn.comNeoGenomics’ Strong Q3 Performance and Growth Potential Drive Buy RecommendationNovember 5, 2024 | markets.businessinsider.comNeoGenomics’ Strong Financial Performance and Growth Potential Earns Buy RatingNovember 5, 2024 | markets.businessinsider.comNeoGenomics, Inc. (NEO) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comNeoGenomics, Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 5, 2024 | seekingalpha.comNeoGenomics (NASDAQ:NEO) Updates FY 2024 Earnings GuidanceNeoGenomics (NASDAQ:NEO) updated its FY 2024 earnings guidance. The company provided EPS guidance of 0.080-0.100 for the period, compared to the consensus estimate of 0.060. The company also issued revenue guidance of $655.0 millionillion-$667.0 millionillion, compared to the consensus estimate of $661.7 millionillion.November 5, 2024 | marketbeat.comNeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating on tNovember 5, 2024 | marketbeat.comEmerald Advisers LLC Cuts Position in NeoGenomics, Inc. (NASDAQ:NEO)Emerald Advisers LLC trimmed its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 8.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,682,214 shares of theNovember 3, 2024 | marketbeat.comNeoGenomics (NEO) to Release Earnings on TuesdayNeoGenomics (NASDAQ:NEO) will be releasing earnings before the market opens on Tuesday, November 5, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=635831)October 29, 2024 | marketbeat.comNeoGenomics gains conditional approval for solid tumour assays in New YorkOctober 23, 2024 | msn.comNeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor TestOctober 22, 2024 | finance.yahoo.comNeoGenomics (NASDAQ:NEO) Shares Down 2.5% - Here's WhyNeoGenomics (NASDAQ:NEO) Trading Down 2.5% - Time to Sell?October 16, 2024 | marketbeat.comRenaissance Technologies LLC Cuts Holdings in NeoGenomics, Inc. (NASDAQ:NEO)Renaissance Technologies LLC cut its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 89.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,300 shares of the medOctober 13, 2024 | marketbeat.comNeoGenomics Unveils AML ExpressOctober 8, 2024 | baystreet.caNeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid LeukemiaOctober 8, 2024 | finance.yahoo.comSei Investments Co. Has $3.66 Million Position in NeoGenomics, Inc. (NASDAQ:NEO)Sei Investments Co. raised its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 152.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 263,761 shares of the medical research company'sOctober 3, 2024 | marketbeat.comNeoGenomics Inc (NEO) Shares Up 3.95% on Oct 2October 2, 2024 | gurufocus.comPoint72 Asset Management L.P. Has $14.31 Million Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)Point72 Asset Management L.P. lessened its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 53.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,031,608 shares of the medicalOctober 1, 2024 | marketbeat.comDimensional Fund Advisors LP Has $46.11 Million Stake in NeoGenomics, Inc. (NASDAQ:NEO)Dimensional Fund Advisors LP lifted its position in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 7.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,324,624 shares of the medical research compaSeptember 30, 2024 | marketbeat.comBrokers Offer Predictions for NeoGenomics, Inc.'s FY2024 Earnings (NASDAQ:NEO)NeoGenomics, Inc. (NASDAQ:NEO - Free Report) - William Blair boosted their FY2024 earnings per share (EPS) estimates for NeoGenomics in a note issued to investors on Tuesday, September 24th. William Blair analyst A. Brackmann now forecasts that the medical research company will post earnings of (September 27, 2024 | marketbeat.comQ4 2025 EPS Estimates for NeoGenomics, Inc. Cut by William Blair (NASDAQ:NEO)NeoGenomics, Inc. (NASDAQ:NEO - Free Report) - Equities research analysts at William Blair lowered their Q4 2025 earnings per share (EPS) estimates for shares of NeoGenomics in a research note issued to investors on Tuesday, September 24th. William Blair analyst A. Brackmann now anticipates thatSeptember 26, 2024 | marketbeat.comFred Alger Management LLC Has $25.45 Million Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)Fred Alger Management LLC lowered its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 21.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,834,912 shares of the medical research company's stock after selling 504,854 shares during theSeptember 26, 2024 | marketbeat.comWhy CEO of Bay Area 'liquid biopsy' cancer test maker is stepping downSeptember 25, 2024 | bizjournals.comFreenome Announces CEO TransitionSeptember 25, 2024 | finance.yahoo.comNeoGenomics Hold Rating Maintained Amidst Ongoing Legal Challenges and MRD Assay Development UncertaintySeptember 25, 2024 | markets.businessinsider.comNeoGenomics' (NEO) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $19.00 target price on shares of NeoGenomics in a report on Wednesday.September 25, 2024 | marketbeat.comExpert Ratings For NeoGenomicsSeptember 24, 2024 | benzinga.comNeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 LitigationSeptember 24, 2024 | finance.yahoo.comBenchmark Reaffirms Buy Rating for NeoGenomics (NASDAQ:NEO)Benchmark restated a "buy" rating and issued a $18.00 target price on shares of NeoGenomics in a research note on Tuesday.September 24, 2024 | marketbeat.comFirst Light Asset Management LLC Acquires 480,396 Shares of NeoGenomics, Inc. (NASDAQ:NEO)First Light Asset Management LLC lifted its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 14.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,782,561 sharesSeptember 24, 2024 | marketbeat.comNeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Blair William & Co. ILBlair William & Co. IL lessened its stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 13.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 409,182 shares of the medical research company's stock after selling 63,68September 22, 2024 | marketbeat.comNeoGenomics, Inc. (NASDAQ:NEO) Stock Position Boosted by American Century Companies Inc.American Century Companies Inc. boosted its position in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 5.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,261,756 shares of the medical research company's stock afteSeptember 17, 2024 | marketbeat.comNeoGenomics, Inc. (NASDAQ:NEO) Given Average Rating of "Moderate Buy" by AnalystsNeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the companySeptember 16, 2024 | marketbeat.comNeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized TreatmentSeptember 11, 2024 | finance.yahoo.comNeoGenomics (NASDAQ:NEO) Shares Down 3.2% NeoGenomics (NASDAQ:NEO) Stock Price Down 3.2%September 9, 2024 | marketbeat.comNeoGenomics, Inc. (NASDAQ:NEO) Shares Acquired by Candriam S.C.A.Candriam S.C.A. raised its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 29.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 487,026 shares of the medical research company's stockSeptember 9, 2024 | marketbeat.comEmerald Advisers LLC Cuts Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)Emerald Advisers LLC lowered its stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 3.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,844,615 shares of the medical research company's stock after seSeptember 8, 2024 | marketbeat.comNeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 29, 2024 | businesswire.com Get NeoGenomics News Delivered to You Automatically Sign up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners… Claim your FREE 2024 Gold Guide NEO Media Mentions By Week NEO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NEO News Sentiment▼0.310.47▲Average Medical News Sentiment NEO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NEO Articles This Week▼53▲NEO Articles Average Week Get NeoGenomics News Delivered to You Automatically Sign up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bilibili News MARA News Lyft News QXO News Etsy News Nuvei News TriNet Group News Alight News DXC Technology News Payoneer Global News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NEO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeoGenomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
